

● International Seminar on the State of the Art in Native Mass Spectrometry



Shanghai Institute of Materia Medica and Bruker are going to hold an academic seminar on ***the State of the Art in Native Mass Spectrometry*** in Shanghai on April 29th. This is one day colloquium consisting oral presentation and discussion, focused on the advanced native mass spectrometry, instrumentation and the practice in drug discovery, particularly on the new active molecule screening from natural products. It is a great chance to talk with international researchers. Looking forward you to join the Seminar.

Address : No.699 Bi Bo Road, Pudong Shanghai
CHAPEL (花园宴会厅), Parkyard hotel (博雅酒店)

Agenda : Apr 29, 2019, Monday

13:00—13:30 Registration

13:30—13:40 Welcome *Prof. Ye Yang, Shanghai Institute of Materia Medica, CAS*

14:40—15:20 **Native Top-Down Mass Spectrometry for Structural Biology and Defining Protein-Ligand Interactions** *Prof. Joseph A. Loo, University of California, Los Angeles, USA*

15:20—16:00 **Native Mass Spectrometry in Drug Discovery: Fragment-based Drug Discovery** *Prof. Ronald J Quinn, Griffith University, Australia*

16:00—16:30 Tea Break

16:30—17:10 **Biophysical and Structural Characterization of Protein Complexes and Therapeutic Antibodies by Native Mass Spectrometry and Top-Down Fragmentation** *Dr. Weidong Cui, Senior Scientist, Amgen, USA*

17:10—17:50 **Maximizing native mass spectrometry for drug discovery – 20 years of Pharma experience** *Dr. Michael Greig, Director, US Pharma/Biopharma, Bruker Daltonics, USA*

17:50—18:00 Q&A

Enquiry: yiting.yu@bruker.com 13370119923

Free registration : <http://bruker-marketing.actonsoftware.com/acton/form/4047/0207:d-0001/0/-/-/-/-/index.htm>



Mobile
registration

● Speaker Introduction

Professor Joseph A. Loo, University of California, Los Angeles, USA

Joseph A. Loo is a Professor in the Department of Biological Chemistry, David Geffen School of Medicine, and in the Department of Chemistry & Biochemistry at the University of California, Los Angeles (UCLA).

He is also a member of UCLA/DOE Institute for Genomics and Proteomics and the UCLA Molecular Biology Institute. His research interests include analytical chemistry, the mass spectrometry characterization of peptides and proteins and post-translational modifications, and their application for proteomics and disease biomarkers.



He is the author of over 300 scientific publications. He is on the Editorial Boards of several scientific journals, and currently he is the Editor-in-Chief for the *Journal of the American Society for Mass Spectrometry*. He has held leadership and advisory positions with scientific organizations, including membership on the Board of Directors for the American Society for Mass Spectrometry (ASMS) and the US Human Proteome Organization (US HUPO).


Before he joined UCLA in 2001, he was an Associate Research Fellow and Group Leader of the Biological Mass Spectrometry and Proteomics Teams at Parke-Davis Pharmaceutical (currently Pfizer Global Research), Ann Arbor, MI. Dr. Loo received his Ph.D. in analytical chemistry from Cornell University with Professor Fred W. McLafferty, where he worked on the development of high resolution mass spectrometry for bioanalytical applications. He carried out research as a post-doctoral fellow, and later as a Senior Scientist, at Pacific Northwest National Laboratory (Richland, WA) with Dr. Richard Smith on the development of electrospray ionization mass spectrometry and capillary electrophoresis for protein characterization.

● Speaker Introduction

Professor Ronald J. Quinn, Griffith University, Australia

Ron Quinn PhD is Professor of Chemistry. He received his B.Sc. and Ph.D. (with Ken Cavill) in Chemistry from UNSW. After postdoctoral training with Bob Pettit at Arizona State University, Richard Moore and Ted Norton at the University of Hawaii, and Rod Rickards at ANU he joined the Roche Research Institute for Marine Pharmacology in Sydney in 1974. He commenced his independent career in 1982 at Griffith University.

His interests focus on biodiscovery (natural products) for tuberculosis, malaria, and Parkinson's disease; Fragment-based drug discovery (using low MW natural products); Native state mass spectrometry; NMR metabolomics; Medicinal chemistry and Artificial Intelligence. He has ongoing interests in 'Ancient Knowledge : Modern Methods' applied to TCM. via Joint Laboratories with the Shanghai Institute of Materia Medica and the Guangxi University of Chinese Medicine.



He has 287 journal articles, 16 book chapters and 11 patents. He has 41 Ph.D. graduates. He has a H-index of 40 and 6,670 citations (Researcher ID A-7931-2008). He was elected to the Australian Academy of Technology and Engineering in 2003 and in 2010 was recognized with a **Member of the Order of Australia (AM) Award**. Fellow, Royal Australian Chemical Institute (RACI), elected 1999

2018 Chinese Academy of Science (CAS) President's Distinguished Scientist Award

2016 Jack L. Beal Award of the Journal of Natural Products

2016 Most Innovative Paper published in Planta Medica in 2015 from the Society for Medicinal Plant and Natural Product Research, Germany

2016 Paul J. Scheuer Award in Marine Natural Products for Outstanding Contribution to the Field, University of Hawaii Foundation, USA

2015 Vice Chancellor's Research Excellence Award for Lifetime Research Leadership

2015 Griffith Sciences Pro Vice Chancellor's Excellence Award for Research Leadership

2013 McCullough Robertson LSQ (Life Sciences Queensland) Industry Excellence Award

2012 Queensland Museum Medal for discovery of many new life forms as a consequence of biodiscovery

2009 Vice Chancellor's Research Excellence Award for Research Leadership

2007 Project of the Year 2007, Medicines for Malaria Venture (MMV), Geneva, Switzerland,

2004 Adrien Albert Award, Royal Australian Chemical Institute

1991-1992 Fellow, Foundation for Promotion of Cancer Research, National Cancer Center Research Institute, Tokyo, Japan,

● Speaker Introduction

Dr. Weidong Cui, Senior Scientist, Amgen, USA

Weidong Cui obtained his Ph.D. with Bixian Peng and Zhen Gao at the Chinese Academy of Sciences in 1998. He spent postdoctoral and guest researcher stays with Chava Lifshitz at the Hebrew University of Jerusalem, James P. Reilly at Indiana University-Bloomington, Stephen E. Stein and Michael R. Zachariah at National Institute of Standards and Technology and University of Maryland College Park, and Peter B. O'Connor and Catherine E. Costello at Boston University. In 2009, he took a staff position the NIH/NIGMS (formerly NCRR) Biomedical Mass Spectrometry Resource led by Michael L. Gross at Washington University in St. Louis where he developed methods and performed research in native MS, top-down MS, high-field FTICR, protein assemblies, and MS-based protein biophysics. In 2012, he assumed administration responsibilities on the operation of the MS Facility of the Chemistry Department at Washington University in St. Louis. Last year, he joined Amgen in Cambridge of Massachusetts as senior scientist of pivotal attribute sciences in the Process Development Organization.



Dr. Michael Greig, Director, US Pharma/Biopharma, Bruker Daltonics

Mike Greig joined Bruker in 2018 as the Director of the US Pharma/Biopharma Business Unit for Bruker Daltonics. In the previous 20 years, he worked at Pfizer in Drug Discovery - most recently leading the Protein Dynamics Group, a core biological mass spectrometry research group focusing on Oncology. During his two decades at Pfizer, he directed labs performing everything from high throughput analysis of small molecule libraries using supercritical fluid-MS, protein NMR, native mass spectrometry, HDX-MS for structural biology, protein turnover, fragment-based drug design, to proteomics. He also spent several years at Ionis Pharmaceuticals managing an oligonucleotide based mass spectrometry research lab and worked at Revlon Science Institute as a polymer and analytical chemist. He has taught over 25 mass spectrometry classes at various scientific conferences and companies worldwide, was a Keynote speaker at the International Mass Spectrometry Conference, a member of the Lab Automation Scientific Committee (now SLAS), member of National High Magnetic Field Laboratory FTICR MS Advisory Panel. Mike has over 50 scientific publications ranging from PK properties of oligonucleotides in mice, native MS of biological complexes, HDX to identify resistance mechanisms in oncology, to SFC/MS of small molecule libraries.



Venue Information

Parkyard hotel 博雅酒店

No.699 Bi Bo Road, Pudong Shanghai 上海市浦东张江高科技园区碧波路699号

